Overview A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis Status: RECRUITING Trial end date: 2028-12-30 Target enrollment: Participant gender: Summary A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.Phase: PHASE1 Details Lead Sponsor: Cullinan Therapeutics Inc.